Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy


Karacin C., Eren T., Zeynelgil E., Imamoglu G. I., Altinbas M., Karadag I., ...More

FUTURE ONCOLOGY, vol.17, pp.4447-4456, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17
  • Publication Date: 2021
  • Doi Number: 10.2217/fon-2021-0597
  • Journal Name: FUTURE ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.4447-4456
  • Keywords: cancer, chemotherapy, COVID-19, immunogenicity, immunotherapy, monoclonal antibody, safety, tumors, vaccine
  • Recep Tayyip Erdoğan University Affiliated: Yes

Abstract

Aim: To evaluate the immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Methods: This multicenter, prospective, observational study was conducted with 47 patients receiving active systemic therapy for cancer. CoronaVac was administered as two doses (3 mu g/day) on days 0 and 28. Antibody level higher than 1 IU/ml was defined as 'immunogenicity.' Results: The immunogenicity rate was 63.8% (30/47) in the entire patient group, 59.5% (25/42) in those receiving at least one cytotoxic drug and 100% (five of five) in those receiving monoclonal antibody or immunotherapy alone. Age was an independent predictive factor for immunogenicity (odds ratio: 0.830; p = 0.043). Conclusion: More than half of cancer patients receiving active systemic therapy developed immunogenicity.